But first the good news:
>>HERCULES, Calif., Sept. 21 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (Amex: BIO.A; BIO.B) announced today that the company intends to resume repurchasing its common stock via market purchase or privately negotiated transactions. This is a continuation of a partially completed ten million dollar ($10,000,000) common share repurchase program, which was authorized in 1998.
``The recent decline in the price of our stock provides the opportunity to improve shareholder value, cover our future obligations under the company's employee stock purchase and option plans, and take advantage of the American Stock Exchange's recent changes in stock repurchase program requirements,'' said David Schwartz, President and Chief Executive Officer.<<
snip
Cheers, Tuck |
